Now Trading in Tel Aviv: America's Most-Shorted Biotech Stocks
- Companies benefit as index funds shore up share prices
- `For the Israeli public, this isn’t necessarily a good thing'
Pedestrians pass the entrance to the Tel Aviv Stock Exchange.
Photographer: Ariel Jerozolimski/BloombergThis article is for subscribers only.
Israel has a reputation as a hotbed of tech innovation, yet the Tel Aviv Stock Exchange hasn’t seen much benefit as many of the country’s best startups have offered their shares in the U.S. instead. Now, an effort to get American companies to go the other direction is starting to pay off.
Four U.S. health care companies have completed dual listings on the bourse this year, including generic-drug giant Mylan NV on Nov. 4. As many as 10 more such deals are in the works, according to law firm Pearl Cohen.